About Pfizer New Zealand: Breakthroughs that change patients’ lives™
Every day, Pfizer colleagues work to provide improved health outcomes by supporting preventions, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as a World leading biopharmaceutical company, we collaborate with health care providers, governments and local communities to support and expand access to reliable and affordable health care for the community.
Pfizer Anti-Infectives has undertaken to prioritise research, education and drug development initiatives designed to help address the critical need for novel antimicrobial medicines, a better understanding of bacterial antibiotic resistance and projects to enhance antimicrobial stewardship.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care.
The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics.
BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family.
For more information on BD, please visit https://www.bd.com/en-au
GSK New Zealand has distributed ViiV Healthcare medicines since 2009 as an extension to our long standing commitment to the treatment of HIV. GSK is the only pharmaceutical company to tackle the three ‘priority’ diseases identified by the World Health Organization: HIV/AIDS, tuberculosis and malaria. Our mission is to help people do more, feel better, live longer. GSK and ViiV Healthcare are committed to the support of the New Zealand HIV community.
Abacus dx creates value by connecting innovative global suppliers with Australasian customers. We are proud to have recently partnered with Immunexpress and T2 Biosystems. Both companies offer tests that revolutionize sepsis diagnosis, patient management and treatment, with actionable results available in a few hours.
Merck Sharp & Dohme (New Zealand) Limited (MSD) is a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. MSD was established in New Zealand in 1962.
In New Zealand, MSD provides medicines, vaccines and biologic therapies across a broad range of therapeutic areas. These include; oncology, anaesthesia, HIV/AIDS, antibacterials/antifungals and immunisations.
MSD is one of the few pharmaceutical companies still conducting clinical trials in New Zealand and as at June 2020 invested approximately $NZ78 million in local clinical research.1 Current research programs include oncology, infectious diseases, endocrinology, chronic cough and vaccines.*
References: *MSD NZ Data on File
Copyright © 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Kenilworth, NJ, USA. All rights reserved. NZ-NON-00076 NA 12356 First Issued October 2020
At the NZ Sepsis Conference 2021 this year, we are pleased to showcase the ABL90 Flex Plus, new parameters Crea/Urea, Transcutaneous monitors, Point of Care IT solutions, AQT Immunoassay analyser, Sepsis diagnostics, and HemoCue Haemoglobin testing.
As leaders in acute care diagnostic testing, Radiometer offers a wide selection of Point of Care Diagnostic solutions.
The ABL Blood Gas range provides features and functionality that match any size facility’s needs, including the ABL90 Flex Plus which measures 19 different parameters simultaneously in only 35 seconds.
The AQT90 FLEX immunoassay analyser delivers reliable results with a fast turnaround time. It has the capability to run up to 5 different tests per blood sample. The AQT90 FLEX is a closed-loop system and covers an extensive range of critical biomarkers at POC including: TnI, TnT, NT-proBNP, PCT, CRP, D-Dimer, βhCG.
HemoCue Point of Care devices are also distributed and supported by Radiometer across Australia and New Zealand, for the detection and prevention of anemia, diabetes and infections.
Radiometer is a leading provider of technologically advanced acute care solutions in labs and at the point of care.
Southern Cross Healthcare is New Zealand’s largest independent healthcare network, including a nationwide family of modern surgical hospitals and advanced treatment centres, community-based physiotherapy and rehabilitation service specialists, and workplace mental health and wellness providers. Within the wider healthcare system, we work in partnership with medical specialists, ACC, District Health Boards and health insurance funders.
The Organising Committee welcome all inquiries from the medical industry involved in the management of sepsis and infectious diseases.
Industry will have the opportunity to engage in person, with leading specialists in a range of clinical specialties (including infectious diseases, critical care and emergency medicine) and national leaders in detecting and responding to the deteriorating patient.
Gaining support from our industry partners is integral to making this conference successful. We encourage you to confirm your sponsorship and exhibition space early, which will ensure you maximise branding opportunities and gain valuable exposure in the lead up to the conference.
A variety of sponsorship and exhibition opportunities are available. Please contact our Conference Managers to express your interest and receive the latest updates.